Business Context and Reporting Period
Company: Icecure Medical Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: February 2026 (Report dated February 23, 2026)
Context: The filing reports the successful completion of the 5-year patient follow-up in the ICESECRET kidney cancer cryoablation study. The final analysis of this study is expected in the second quarter of 2026.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical study milestones and does not contain financial statements or performance metrics.
Material Changes
No material financial changes versus a prior comparable period are disclosed in this filing. The primary update is the operational milestone regarding the ICESECRET study follow-up completion.
Guidance, Outlook, and Risks
- Outlook: Management expects the final analysis of the ICESECRET study to be released in the second quarter of 2026.
- Management Commentary: The company highlights the successful completion of the 5-year follow-up as a key development for its kidney cancer cryoablation technology.
- Risks and Contingencies: No specific risks or contingencies are detailed in the text of this Form 6-K.
Investor Verification Checklist
- Verify the timeline for the release of the final ICESECRET study analysis (expected Q2 2026).
- Review the full press release (Exhibit 99.1) for detailed clinical data points not summarized in the Form 6-K.
- Monitor upcoming filings for financial impact assessments related to the study results.